Literature DB >> 15297961

Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives.

Debra A Bell1, Teri A Longacre, Jaime Prat, Elise C Kohn, Robert A Soslow, Lora H Ellenson, Anais Malpica, Mark H Stoler, Robert J Kurman.   

Abstract

Although the category of serous borderline ovarian tumor (S-BOT) was established more than 30 years ago, the nomenclature and prognostic significance of various histological features of these neoplasms continues to engender controversy. The Borderline Ovarian Tumor Workshop was held in Bethesda, MD, in August 2003 in an attempt to examine the existing data, establish areas of agreement, and identify areas needing further investigation. This report addresses 6 areas of controversy regarding S-BOT: (1) tumors with and without a micropapillary architecture (typical vs micropapillary type), (2) peritoneal implants, (3) stromal microinvasion, (4) ovarian surface involvement, (5) lymph node involvement, and (6) recurrent tumors. Each of these issues is addressed by summarizing the data in the literature on which the discussions were based, areas of agreement that emerged, divergent opinions and the reasoning behind them, and the conclusions of the participants with recommended nomenclature.

Entities:  

Mesh:

Year:  2004        PMID: 15297961     DOI: 10.1016/j.humpath.2004.03.005

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  28 in total

Review 1.  Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.

Authors:  Russell Vang; Ie-Ming Shih; Robert J Kurman
Journal:  Adv Anat Pathol       Date:  2009-09       Impact factor: 3.875

2.  Tubal origin of ovarian low-grade serous carcinoma.

Authors:  Chenglu Chen; Jie Li; Guang Yao; Setsuko K Chambers; Wenxin Zheng
Journal:  Am J Clin Exp Obstet Gynecol       Date:  2013-12-15

Review 3.  A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract.

Authors:  Robert A Soslow; Rajmohan Murali
Journal:  Semin Diagn Pathol       Date:  2017-11-20       Impact factor: 3.464

4.  Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.

Authors:  Russell Vang; Charlotte G Hannibal; Jette Junge; Kirsten Frederiksen; Susanne K Kjaer; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2017-06       Impact factor: 6.394

5.  BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.

Authors:  Rachel N Grisham; Gopa Iyer; Karuna Garg; Deborah Delair; David M Hyman; Qin Zhou; Alexia Iasonos; Michael F Berger; Fanny Dao; David R Spriggs; Douglas A Levine; Carol Aghajanian; David B Solit
Journal:  Cancer       Date:  2012-08-28       Impact factor: 6.860

Review 6.  Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma.

Authors:  Xiaoxiang Chen; Jing Zhang; Zhihong Zhang; Hongxia Li; Wenjun Cheng; Jinsong Liu
Journal:  Hum Pathol       Date:  2013-07-11       Impact factor: 3.466

Review 7.  Epithelial borderline ovarian tumor: Diagnosis and treatment strategy.

Authors:  Kimio Ushijima; Kouichiro Kawano; Naotake Tsuda; Shin Nishio; Atsumu Terada; Hiroyuki Kato; Kazuto Tasaki; Ken Matsukuma
Journal:  Obstet Gynecol Sci       Date:  2015-05-19

Review 8.  Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.

Authors:  S Avril
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

9.  Matrix metalloproteinase-8 promoter gene polymorphisms in Mexican women with ovarian cancer.

Authors:  Fabian Arechavaleta-Velasco; Rocio Cuevas-Antonio; Pablo Dominguez-Lopez; Isaias Estrada-Moscoso; Fazlollah Shahram Imani-Razavi; Moises Zeferino-Toquero; Laura Diaz-Cueto
Journal:  Med Oncol       Date:  2014-07-18       Impact factor: 3.064

Review 10.  Genomic analysis of epithelial ovarian cancer.

Authors:  John Farley; Laurent L Ozbun; Michael J Birrer
Journal:  Cell Res       Date:  2008-05       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.